

May 7, 2025

To

BSE Limited

Phiroze Jeejeebhoy Towers, 25th Floor, Dalal
Street, Mumbai – 400 001

The National Stock Exchange of India Ltd

Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Completion of tenure of an Independent Director

Pursuant to Regulation 30 of SEBI Listing Regulations, we would like to inform you that Dr. Nirmala Murthy (DIN: 00734866) has completed her second term as an Independent Director and consequently ceased to be a Director of the Company w.e.f. the close of working hours on May 7, 2025.

The details as required under Regulation 30 of the SEBI Listing Regulations, with respect to the above retirement is enclosed as **Annexure A**.

This is for your information and records.

Thanking you

Yours Sincerely,

For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Annexure A**Details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015****Details of Dr. Nirmala Murthy (DIN: 00734866):**

Sl. No.	Particulars	Remarks
1.	Reason for change	Retirement on account of end of second term as an Independent Director of the Company on May 7, 2025
2.	Date of cessation as a Director	With effect from the close of working hours on May 7, 2025
3.	Brief Profile	Not Applicable
4.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable